March 2026 Sees Surge in Global Healthcare M&A with Multiple Deals Exceeding $5 Billion

　　【Pharmaceutical Network Industry DynamicsSince March 2026, the global healthcare sector has seen a surge in M&A activity, with large-scale cross-border deals being particularly prominent. Companies such as Abbott, Medtronic, Agilent, and GE Healthcare have all completed acquisition transactions exceeding $5 billion. Notably, Abbott's $230 billion acquisition of Exact Sciences set a new record for the largest transaction amount in the global diagnostics industry.
 

On March 20, Abbott announced the completion of its acquisition of Exact Sciences in a deal worth approximately $21 billion (equivalent to about 145 billion yuan). Exact Sciences is a leading company in the field of cancer screening and molecular diagnostics in the United States. Its core products include non-invasive colorectal cancer screening tests, as well as pipelines under development for early detection of multiple types of cancers and minimal residual disease testing.
 

For Abbott, this acquisition will help it transition from traditional in vitro diagnostics to the high-growth track of "early cancer screening + precision oncology." It is reported that Abbott's businesses cover multiple fields such as immunoassay diagnostics, clinical chemistry, and POCT, but it has gaps in early cancer screening and molecular diagnostics. The products and operations of Exact Sciences can precisely fill this void.
 

News on March 18, GE Healthcare announced that it has completed the previously announced acquisition of Intelerad for $2.3 billion (approximately RMB 15.87 billion). Intelerad owns imaging software and digital enterprise workflow solutions and has significant influence in the outpatient medical field. In November last year, GE Healthcare officially announced that it would acquire Intelerad for $2.3 billion.
 

Through this acquisition, GE Healthcare will further achieve its goal of tripling its cloud-enabled product portfolio by 2028. It will also expand its business scope to high-growth specialty clinics and the rapidly developing outpatient healthcare environment, creating complementary advantages.
 

On March 10, Medtronic announced that it had agreed to acquire Scientia Vascular, headquartered in the United States, for a transaction valued at $5.5 billion (approximately RMB 37.75 billion), aiming to expand its stroke treatment product line. This acquisition is expected to be completed in the first half of fiscal year 2027.
 

Data shows that Scientia Vascular mainly operates guidewires and catheter products for cerebral vascular interventional surgeries. For Medtronic, these guidewire and catheter product lines can be seamlessly integrated with Medtronic's existing neurovascular products, supporting the entire process of surgeries for hemorrhagic stroke and acute ischemic stroke.
 

On March 9, Agilent Technologies announced that it would acquire Biocare Medical, a privately held clinical pathology company, for $950 million in an all-cash transaction, further expanding its presence in the clinical diagnostics sector. The deal is expected to close in the fourth quarter of fiscal year 2026.
 

It is reported that this acquisition is another significant move by Agilent in the life sciences and diagnostics field. By leveraging Biocare Medical's product portfolio and customer resource advantages in the tissue diagnostics sector, Agilent will further expand its business footprint in the clinical pathology diagnostics space and enhance its market competitiveness in related niche areas.
 

Overall, the global healthcare M&A boom in 2026 marks that industry competition has upgraded from single product competition to systematic competition of "technology platform + pipeline integration + ecosystem construction." In the future, platform leaders who can both acquire key technologies through precise M&A and efficiently integrate data and services will become the winners in the competition.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.